Will President Trump's Tylenol Claims Hurt These 2 Leading Pharmaceutical Stocks?

News flow can have a material impact on how investors view a stock. Sometimes, however, the news leaks before it actually hits the press. That's what happened leading up to the Food and Drug Administration's (FDA) warning that pregnant women should avoid taking acetaminophen, which sold under the brand name of Tylenol, because of the potential risks it poses to unborn children. But there's so much more to consider when you look at Tylenol maker Kenvue (NYSE: KVUE) and its former parent, Johnson & Johnson (NYSE: JNJ).News on Wall Street often travels a well-worn path, with a rumor coming first before the actual news. It's why the saying "buy on the rumor, sell on the news" exists. With Tylenol, there were rumors swirling about a pending announcement from President Donald Trump's FDA well before that announcement, along with a presidential news conference, actually came about. Anyone who closely watches Kenvue, which sells consumer staples and over-the-counter drugs, probably wasn't shocked by the announcement.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool